Insights / Scientific Posters
Keep up with Primrose Bio’s
Scientific Posters
Presented at the World Vaccine Congress 2026: Extracellular Secretion and Non-canonical Amino Acid (ncAA) Incorporation: New Capabilities Supporting Conjugate Vaccine Discovery and Development
ABSTRACT: Efficient production of vaccine carrier proteins and antigens is paramount to ensuring access to affordable conjugate vaccines. Streamlined conjugation technologies improve product quality...
Presented at the BioProcess International US West (BPI West) 2026: Engineered Fusion Partners Enabling HighYield Recombinant Peptide Production
ABSTRACT: Peptide therapeutics are a fast-growing class of medicines, but traditional solid phase peptide synthesis (SPPS) has limitations in cost, scalability, and environmental impact. Pfenex...
Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs As an example of the workflow, an...
Presented at Antibody Engineering & Therapeutics US 2025: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs. As an example of the workflow, an...
Presented at 13th International mRNA Health Conference: Prima RNApols™: Engineered Enzymes Powering the Future of mRNA Therapeutics
ABSTRACT: The field of mRNA therapeutics is rapidly developing across a wide range of applications, including infectious diseases, rare disorders, protein replacement, and cancer immunotherapy....
Presented at PEGS EU 2025: Preclinical Development of a VHH-ADC Using the Pfenex Platform
ABSTRACT: Amber suppression technology has matured over the last 25 years, enabling incorporation of non-canonical amino acids (ncAAs) that allow targeted conjugation and expanded therapeutic...
Presented at TIDES USA 2025: Prima RNApols™ ExTend: rewriting the rules of long mRNA manufacturing
ABSTRACT: The success of mRNA COVID-19 vaccines has transformed the therapeutic landscape, accelerating the development of mRNA-based treatments across diverse applications. While in vitro...
Presented at TIDES USA 2025: Advancing mRNA therapeutics with high performance RNA polymerases
ABSTRACT: RNA has emerged as a critical tool in modern biotechnology and therapeutics, with applications ranging from vaccine development to gene therapy. mRNA is synthesized by in vitro...
Presented at PEGS US 2025: High-Throughput Expression and Purification of Untagged RNA Polymerase Variants: Advancements in the Pfenex Expression Technology® Platform
ABSTRACT: Primrose Bio's Pfenex Expression Technology® (Pfenex) platform has established itself as a robust, scalable solution for recombinant protein production, as evidenced by its role in six...
